Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer

Area of Science:

• Oncology
• Vascular Biology
• Pharmacology

Background:

• Bevacizumab is the first approved vascular endothelial growth factor (VEGF)-targeted agent for metastatic colorectal cancer.
• Its application is expanding to other tumor types and earlier disease stages (adjuvant setting).
• Maximizing bevacizumab's efficacy requires exploring novel therapeutic strategies.

Purpose of the Study:

• To review current research on bevacizumab and other VEGF-targeted agents.
• To identify strategies for enhancing the clinical benefits of VEGF inhibition.
• To address unanswered questions regarding optimal dosing, scheduling, and mechanisms of action.

Main Methods:

• Review of preclinical and clinical research on VEGF-targeted agents.
• Exploration of combination therapies: dual inhibition, combination with other targeted agents (e.g., HER2, EGFR inhibitors), and metronomic chemotherapy.
• Discussion of ongoing research into optimal dosing and scheduling.
• Emphasis on mechanistic studies in humans to understand vascular effects.

Main Results:

• Several strategies are under investigation to enhance bevacizumab's efficacy.
• Dual inhibition of VEGF and platelet-derived growth factor signaling targets both endothelial and pericyte components of tumor vasculature.
• Combining VEGF inhibitors with other targeted therapies or metronomic chemotherapy is being explored.
• Optimal dose and schedule remain key unanswered questions.

Conclusions:

• Bevacizumab and other VEGF-targeted agents hold promise beyond metastatic colorectal cancer.
• Combination strategies and further mechanistic studies are crucial for optimizing treatment outcomes.
• Development of surrogate clinical endpoints, like noninvasive imaging, will aid future research.